|Position||Trades||Duration||Win rate||Win/loss||Avg win||Avg loss||Return|
|Position||Trades||Duration||Win Rate||Win/Loss||Avg Win||Avg Loss||Return|
Clinuvel Pharmaceuticals (CUV.AX)
DAILY VOLUME INDEX
Trading: HOLD @ $33.11
Signal Strength: MEDIUM
Clinuvel Pharmaceuticals (ASX:CUV) current accumulation has given strength to the share price and the continuation of bullish trading conditions. Currently, the DVI is 3303.
Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading entry. Indicator can be applied to the short/medium term timeframe, but the best results are obtained with larger cyclical swings in-line with the trend direction. This accumulation / distribution oscillator can provide guidance on the money flow direction from the companies recent trading.
The daily volume index (DVI) is the amount of individual securities traded in a day on average over a specified period of time. Trading activity relates to the liquidity of a security. When average daily trading volume is high the stock can be easily traded and has high liquidity if trading volume is not very high and the security will tend to be less expensive because people are not as willing to buy it. As a result average daily trading volume can have an effect on the price of the security.
Calculation: Daily Volume Index (DVI):
1) [Close]-[Average price] / [Average price] x [Volume];
PROFILE: Clinuvel Pharmaceuticals (CUV.AX)
Stock Exchange: ASX
Company: Clinuvel Pharmaceuticals
Ticker Codes: | CUV.AX | ASX:CUV |
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing drugs for the treatment of a range of severe skin disorders. Its lead drug compound is SCENESSE, a medicinal photoprotective and repigmentation drug that has completed Phase II and III trials in the United States and Europe, which is used for the prevention of phototoxicity in adults with erythropoietic protoporphyria. The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue that acts as a potent skin protectant; and VLRX001, an addition to the family of melanocortin analogues, which provoke increased and prolonged cellular activity. It has operations in Europe, the United States, and Singapore. The company is headquartered in Melbourne, Australia.
|KAR Karoon Gas Australia||1.1||9||1,448,127||3,672||BULLISH|
|AYS Amaysim Australia||0.78||5.4||268,838||1,660||BULLISH|
|ANG Austin Engineering||0.2||5.3||34,915||15,494||BULLISH|
|AGI Ainsworth Game Technology||0.72||4.4||110,004||487||BULLISH|
|SXY Senex Energy||0.36||4.4||3,369,730||31,016||BULLISH|
|CLQ Clean Teq Holdings||0.37||4.2||1,734,161||27,146||BULLISH|
|MVF Monash IVF||1.44||3.6||383,757||4,105||BULLISH|
|ONT 1300 Smiles||6.4||3.6||782||23||BULLISH|